Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 769 of 5804
-
Immunotherapy combo shows promise for early lung cancer
Disease control OngoingNivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype mAb that binds PD-1 on activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7 H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the host antitumo…
Phase: PHASE2 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo therapy for Hard-to-Treat gut tumors enters final testing phase
Disease control Recruiting nowNeuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard…
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug cocktail shows promise in larynx cancer without surgery
Disease control OngoingThis phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New shot aims to stop liver damage in rare genetic disease
Disease control CompletedThe purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Simple stool test could revolutionize colon cancer screening
Diagnosis Recruiting nowColon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, due to a variety of factors, including af…
Sponsor: University of Michigan Rogel Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
New hope for Hard-to-Treat breast cancer: experimental drug ARV-471 shows promise
Disease control CompletedThis is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in patients with estrogen receptor positive/human epidermal growth factor receptor 2 neg…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can pushing blood pressure lower save stroke Survivors' hearts?
Disease control OngoingElevated blood pressure (BP) consists of a major public health concern especially in low and middle income countries. Besides being a highly prevalent condition, it is also a risk factor for several major cardiovascular events including stroke (which consists of the second leadin…
Phase: NA • Sponsor: Hospital Israelita Albert Einstein • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a targeted pill boost lymphoma cure rates?
Disease control Recruiting nowBackground: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could less radiation be enough for HPV throat cancer? new trial aims to find out.
Disease control Recruiting nowThe current standard treatment option for Human Papillomavirus (HPV) or p16-positive oropharyngeal cancer is full-dose radiation combined with chemotherapy. Results with chemotherapy combined with full-dose radiation therapy leads to high rates of cure; this has called into quest…
Phase: NA • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
TB prevention breakthrough? 6-Week regimen could replace months of treatment
Prevention Recruiting nowThis study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection (LTBI…
Phase: PHASE2, PHASE3 • Sponsor: Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Could a common drug stop arthritis after a torn ACL?
Prevention Recruiting nowPatients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an …
Phase: PHASE2 • Sponsor: Stanford University • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC
-
HPV vaccine shows promise in cutting cervical lesion risk for HIV-Positive women
Disease control CompletedThis randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV. Vaccines made from HPV peptides or antigens may help the body build an effective …
Phase: PHASE3 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
One pill to rule them all? new combo therapy for PAH shows promise
Disease control CompletedCombination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impac…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New mapping technique may stop arm swelling in breast cancer patients
Disease control OngoingThis phase III trial studies how well axillary reverse mapping works in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast so as to prevent …
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Promising combo for HPV throat cancer hits snag: trial stopped early
Disease control TerminatedThis phase II trial studies the side effects and best dose of ipilimumab, nivolumab, and radiation therapy and how well they work in treating patients with advanced human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. Immunotherapy with monoclonal antibodies…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Vibrating watch may disrupt PTSD nightmares, study finds
Symptom relief CompletedThis study will provide preliminary estimates of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbanc…
Phase: NA • Sponsor: NightWare • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Immune drugs given before surgery show promise against multiple cancers
Disease control OngoingThis study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details…
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New One-Shot knee cartilage repair shows promise in trial
Disease control CompletedArticular cartilage defects in the knee have poor intrinsic healing capacity and may lead to functional disability and osteoarthritis. Cartilage cell therapy using autologous chondrocyte implantation has been established as the first advanced treatment therapy medicinal product. …
Phase: PHASE3 • Sponsor: R.J.H. Custers • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
AI shrinks radiation target, cuts side effects in head and neck cancer
Disease control CompletedElective nodal irradiation has been a longstanding standard-of-care in the management of mucosal squamous cell carcinoma of the head and neck. Recent studies have suggested that reduced elective dose and volume may be a viable approach to improve toxicity. In this study, we are e…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Hope for elderly lung cancer patients: immunotherapy combo under study
Disease control OngoingNon Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have show…
Phase: PHASE3 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC